EIKN · CIK 0001861123
Eikon Therapeutics, Inc.
What Eikon Therapeutics, Inc. owns has not been researched yet. This page is its ownership register, who holds it, and the absence of holdings below means nobody has looked rather than that there is nothing to find.
Eikon Therapeutics, Inc. - Profile
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
- Listed on
- Nasdaq
- Employees
- 384stated 2025
- Incorporated in
- Delaware
- Financial year ends
- 31 December
Source
Address, industry classification, listing and incorporation come from Eikon Therapeutics, Inc.'s own SEC filer record, so the industry is the SEC's dry classification rather than a marketing label. The headcount is the figure the sources below state for 2025. The description was written for this site in August 2026 from Eikon Therapeutics, Inc. Form 10-K for fiscal year 2025 and Eikon Therapeutics, Inc. Form 10-Q for the quarter ended 30 June 2026, not taken from any single article.
Share price
EIKN
Description
Eikon Therapeutics, Inc. is a clinical-stage biopharmaceutical company in Millbrae, California that applies a proprietary single molecule tracking platform to oncology drug discovery. The platform pairs custom-engineered super-resolution microscopy with bespoke automation and machine learning software processing up to one petabyte of data a day, used to observe target proteins inside living human cells. The most advanced candidate, EIK1001, is a systemically administered TLR 7/8 dual-agonist in a roughly 740-patient global Phase 2/3 registrational trial with pembrolizumab in advanced melanoma, alongside a Phase 2 trial in non-small cell lung cancer. EIK1003 and EIK1004, selective PARP1 inhibitors in-licensed from Impact Therapeutics, are in Phase 1/2 trials, and EIK1005, a WRN helicase inhibitor and the first candidate to come out of the platform, has begun Phase 1/2 dosing. Clinical trial collaboration and supply agreements with MSD International Business GmbH cover pembrolizumab supply for three of these studies. Eikon has no revenue: it reported a net loss of $324.2 million for 2025 and $171.4 million for the first half of 2026. It listed on Nasdaq on 6 February 2026 and held $531.2 million in cash and marketable securities at 30 June 2026, which it expects to fund operations into the second half of 2027. Eikon had 384 full-time employees at 31 December 2025.
Who owns Eikon Therapeutics, Inc..
Nothing recorded on this side. That is a sourced finding rather than a gap where the research notes say so: see the notes below.
Select a row or a slice for its provenance: the filing it came from, when it was measured, and the arithmetic behind it if it was modelled.
The full register, from 13F filings
The Register tab above is hand research: a dozen holders, each traced to the filing it came from. This asks the same question of the whole market for the quarter ended 31-mar-2026, where 49 managers reported a position. Broad where the research is deep, and shallow in the ways a 13F always is.
49 managers reported a position, together holding 23.7m shares, or 43.9% of the company. The 40 largest are listed. Percentages are of the 54.1m shares outstanding at 1 May 2026, the count in force when this quarter was measured rather than the count today.
Built from 13F filings, which report US listed, long, US custodied positions only. A register from this source is a floor rather than a level: a holder's true position can be far larger, as BlackRock's ASML stake shows at 1.28m shares in a 13F against 26.3m in its 13G/A. Holdings held through derivatives, outside US custody, or below a manager's reporting obligation do not appear. Where a holder is marked as a family, its total sums several separate filing entities and describes something no single filing describes; the constituent entities and their share counts are listed so the total can be checked. That roll-up can legitimately exceed the family's own Schedule 13G, because a 13G is filed by one legal entity: Vanguard reports Alphabet through ten advisory entities, and The Vanguard Group Inc itself reported zero after its January 2026 disaggregation.
What a reader needs to know to read these numbers
- Added 27 Aug 2026 by scripts/promote_discovered.py. This company reached the site because a covered investor holds it, not because an index listed it: it was a position in a portfolio here with no page of its own. The match was proved by requiring the register built for this CIK to contain the same CUSIP the portfolio held.
- Discovered at CUSIP 282564103, held by bank-of-america, blackrock, bny-mellon, capital-group, citigroup, fidelity-fmr, franklin-resources, geode, invesco, jpmorgan, merck, metlife, morgan-stanley, northern-trust, state-street, vanguard, wells-fargo.
- Holdings are NOT researched. The empty holdings list means nobody has looked at what this company owns, not that it owns nothing, and the page says so.
- Shares outstanding and market cap are null rather than guessed. Neither was captured on the dated sweep that carries every other company here.
Looked for, not found
Recorded rather than filled in. Each of these is a place where a number could have been invented and was not.
- Shares outstanding.
- Market capitalisation.